Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27830241 | 0.81 | L3MBTL1 (0.33) | LMNATP53NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2140521 | 0.79 | PTGER1 (0.35) | LMNATP53NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12101006 | 0.79 | RXFP1 (0.38) | LMNAGAATP53NPC1RAB9A | |
| SCHEMBL11579363 | 0.77 | RAB9A (0.39) | LMNAGAATP53NPC1RAB9A | |
| SCHEMBL18415695 | 0.75 | L3MBTL1 (0.35) | L3MBTL1 | |
| SCHEMBL2754051 | 0.75 | ITGB1 (0.36) | LMNAGAAL3MBTL1 | |
| SCHEMBL2142507 | 0.75 | NPSR1 (0.47) | LMNAGAANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17971480 | 0.74 | ALDH1A1 (0.49) | GAATP53SMN1; SMN2 | |
| SCHEMBL23815752 | 0.71 | GAA (0.44) | LMNAGAATP53NPC1RAB9A | |
| SCHEMBL24630405 | 0.71 | RAB9A (0.36) | TP53NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160228414-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2016-08-11 | — | — | US | disclosed |
| US-9249131-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-02-02 | — | — | US | disclosed |
| US-20150025076-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2015-01-22 | — | — | US | disclosed |
| US-8853415-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-10-07 | — | — | US | disclosed |
| US-8741939-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-06-03 | — | — | US | disclosed |
| US-20140072995-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-03-13 | — | — | US | disclosed |
| US-20130252333-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED | 2013-09-26 | — | — | US | disclosed |
| US-8431605-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2013-04-30 | — | — | US | disclosed |
| EP-2242759-B1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2012-09-12 | — | — | EP | disclosed |
| US-20120004216-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-05 | — | — | US | disclosed |
| US-7973169-B2 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"), such as N-(4,5-Diphenyl-thiazol-2-yl)-benzamide, used for treating genetic disorders; respiratory system disorders | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252333-A1 | Modulators of ATP-Binding Cassette Transporters | CFTR, ABCB1, ABCF1 | LMNA 3392/4885GAA 272/4885TP53 2956/4885 |
| US-20160228414-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCF1 | LMNA 3392/4885GAA 272/4885TP53 2956/4885 |
| US-20120004216-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCF1 | LMNA 3392/4885GAA 272/4885TP53 2956/4885 |
| US-20150025076-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCF1 | LMNA 3417/4885GAA 279/4885TP53 2969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.